Bio-Techne Corporation (TECH)
Price:
59.19 USD
( - -2.73 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
NEWS
What Moved Markets This Week
seekingalpha.com
2025-10-04 06:45:29Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions
zacks.com
2025-09-29 09:25:27TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.
Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications
prnewswire.com
2025-09-26 06:30:00RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section Technologies support spatial multiomic analysis and deeper insights for pathology workflows Research highlights potential role in clinical utility workflows for lymphoid malignancies and B-cell clonality MINNEAPOLIS , Sept. 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced new advancements in its spatial biology portfolio for the RNAscope™ ISH technology and the Lunaphore COMET™.
Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report
prnewswire.com
2025-09-24 06:59:00Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions MINNEAPOLIS , Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate Sustainability Report, underscoring the company's commitment to advancing human health while protecting the planet.
Bio-Techne Corporation (TECH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
seekingalpha.com
2025-09-10 14:36:39Bio-Techne Corporation (NASDAQ:TECH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants James Hippel - Executive VP of Finance & CFO Presentation Unknown Analyst All right. Thank you, everyone, for joining today.
META EXECUTIVE DANE GLASGOW TO JOIN PARAMOUNT AS CHIEF PRODUCT OFFICER, DRIVING TECH INNOVATION AND PRODUCT STRATEGY
prnewswire.com
2025-09-10 13:30:00Highly respected senior technology executive and serial entrepreneur, Glasgow previously served as VP of Product Management for Facebook LOS ANGELES , Sept. 10, 2025 /PRNewswire/ -- Paramount, a Skydance Corporation today announced that Dane Glasgow, a seasoned technology leader with extensive experience in consumer product development and management, digital platforms, and advanced technologies, will join the company as Chief Product Officer.
Bio-Techne Corporation (TECH) Presents At Baird Global Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-09 11:36:18Bio-Techne Corporation (NASDAQ:TECH ) Baird Global Healthcare Conference 2025 September 9, 2025 9:05 AM EDT Company Participants James Hippel - Executive VP of Finance & CFO Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior Research Analyst Catherine Schulte.
ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California
prnewswire.com
2025-09-09 07:00:00ST. PAUL, Minn. , Sept. 9, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that eight (8) G-Rex Grants, totaling nearly $2 million in support, have been awarded to awardees of the California Institute for Regenerative Medicine (CIRM) Manufacturing Network (INFR5) program.
Bio-Techne Corporation (TECH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-03 15:42:53Bio-Techne Corporation (NASDAQ:TECH ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Kim Kelderman - CEO, President & Director Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Great. Good morning.
CMB.TECH announces Q2 2025 results
globenewswire.com
2025-08-28 01:04:00CMB.TECH ANNOUNCES Q2 2025 RESULTS MERGER WITH GOLDEN OCEAN COMPLETED ANTWERP, Belgium, 28 August 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the second quarter ended 30 June 2025. HIGHLIGHTS Corporate highlights: CMB.TECH completed the merger with Golden Ocean on 20 August CMB.TECH is listed on NYSE (CMBT), EURONEXT Brussels (CMBT) and EURONEXT Oslo (CMBTO) Supervisory Board changes: resignation of Mr.
Bio-Techne to Present at Upcoming Investor Conferences
prnewswire.com
2025-08-27 07:00:00MINNEAPOLIS , Aug. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference September 3, 2025 10:15 AM EDT Baird 2025 Global Healthcare Conference September 9, 2025 9:05 AM EDT Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
PRESS RELEASE: Disclosure regarding a transparency notification - Article 14, 1st paragraph, of the Law of 2 May 2007 relating to the disclosure of important shareholdings in listed companies
globenewswire.com
2025-08-27 02:38:00Antwerp, Aug. 27, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) received a transparency notification from Saverco NV on 25 Augustus 2025. Saverco NV has crossed below the transparency threshold of 65%.
PRESS RELEASE: CMB.TECH completes merger with Golden Ocean
globenewswire.com
2025-08-20 03:34:00Antwerp, Aug. 20, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) is pleased to announce that it has successfully completed the stock-for-stock merger between Golden Ocean Group Limited (“Golden Ocean”) and CMB.TECH Bermuda Ltd., a wholly-owned subsidiary of CMB.TECH, with CMB.TECH Bermuda Ltd. as the surviving company, and with CMB.TECH as the issuer of the merger consideration shares (the “Merger”).
ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory
prnewswire.com
2025-08-14 07:00:00ST. PAUL, Minn. , Aug. 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant to develop a modular G-Rex centric CAR T-cell manufacturing platform.
CMB.TECH Business update Q2 2025 results
globenewswire.com
2025-08-14 02:33:00Antwerp, Aug. 14, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its second quarter 2025 earnings prior to market opening on Thursday 28 August 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter. Due to the proximity of the expected closing date of the contemplated stock-for-stock merger between CMB.TECH and Golden Ocean Group Limited (“Golden Ocean”), CMB.TECH already provides preliminary figures related to the Q2 2025 results in this business update.
CMB.TECH's update on the Golden Ocean merger process
globenewswire.com
2025-08-11 03:26:00Antwerp, Aug. 11, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext Brussels: CMBT) (“CMB.TECH”) provides an additional market update on the progress of the contemplated stock-for-stock merger between CMB.TECH and Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) ("Golden Ocean").
What Moved Markets This Week
seekingalpha.com
2025-10-04 06:45:29Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions
zacks.com
2025-09-29 09:25:27TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.
Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications
prnewswire.com
2025-09-26 06:30:00RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section Technologies support spatial multiomic analysis and deeper insights for pathology workflows Research highlights potential role in clinical utility workflows for lymphoid malignancies and B-cell clonality MINNEAPOLIS , Sept. 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced new advancements in its spatial biology portfolio for the RNAscope™ ISH technology and the Lunaphore COMET™.
Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report
prnewswire.com
2025-09-24 06:59:00Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions MINNEAPOLIS , Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate Sustainability Report, underscoring the company's commitment to advancing human health while protecting the planet.
Bio-Techne Corporation (TECH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
seekingalpha.com
2025-09-10 14:36:39Bio-Techne Corporation (NASDAQ:TECH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants James Hippel - Executive VP of Finance & CFO Presentation Unknown Analyst All right. Thank you, everyone, for joining today.
META EXECUTIVE DANE GLASGOW TO JOIN PARAMOUNT AS CHIEF PRODUCT OFFICER, DRIVING TECH INNOVATION AND PRODUCT STRATEGY
prnewswire.com
2025-09-10 13:30:00Highly respected senior technology executive and serial entrepreneur, Glasgow previously served as VP of Product Management for Facebook LOS ANGELES , Sept. 10, 2025 /PRNewswire/ -- Paramount, a Skydance Corporation today announced that Dane Glasgow, a seasoned technology leader with extensive experience in consumer product development and management, digital platforms, and advanced technologies, will join the company as Chief Product Officer.
Bio-Techne Corporation (TECH) Presents At Baird Global Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-09 11:36:18Bio-Techne Corporation (NASDAQ:TECH ) Baird Global Healthcare Conference 2025 September 9, 2025 9:05 AM EDT Company Participants James Hippel - Executive VP of Finance & CFO Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior Research Analyst Catherine Schulte.
ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California
prnewswire.com
2025-09-09 07:00:00ST. PAUL, Minn. , Sept. 9, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that eight (8) G-Rex Grants, totaling nearly $2 million in support, have been awarded to awardees of the California Institute for Regenerative Medicine (CIRM) Manufacturing Network (INFR5) program.
Bio-Techne Corporation (TECH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
seekingalpha.com
2025-09-03 15:42:53Bio-Techne Corporation (NASDAQ:TECH ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Kim Kelderman - CEO, President & Director Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Great. Good morning.
CMB.TECH announces Q2 2025 results
globenewswire.com
2025-08-28 01:04:00CMB.TECH ANNOUNCES Q2 2025 RESULTS MERGER WITH GOLDEN OCEAN COMPLETED ANTWERP, Belgium, 28 August 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the second quarter ended 30 June 2025. HIGHLIGHTS Corporate highlights: CMB.TECH completed the merger with Golden Ocean on 20 August CMB.TECH is listed on NYSE (CMBT), EURONEXT Brussels (CMBT) and EURONEXT Oslo (CMBTO) Supervisory Board changes: resignation of Mr.
Bio-Techne to Present at Upcoming Investor Conferences
prnewswire.com
2025-08-27 07:00:00MINNEAPOLIS , Aug. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference September 3, 2025 10:15 AM EDT Baird 2025 Global Healthcare Conference September 9, 2025 9:05 AM EDT Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
PRESS RELEASE: Disclosure regarding a transparency notification - Article 14, 1st paragraph, of the Law of 2 May 2007 relating to the disclosure of important shareholdings in listed companies
globenewswire.com
2025-08-27 02:38:00Antwerp, Aug. 27, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) received a transparency notification from Saverco NV on 25 Augustus 2025. Saverco NV has crossed below the transparency threshold of 65%.
PRESS RELEASE: CMB.TECH completes merger with Golden Ocean
globenewswire.com
2025-08-20 03:34:00Antwerp, Aug. 20, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) is pleased to announce that it has successfully completed the stock-for-stock merger between Golden Ocean Group Limited (“Golden Ocean”) and CMB.TECH Bermuda Ltd., a wholly-owned subsidiary of CMB.TECH, with CMB.TECH Bermuda Ltd. as the surviving company, and with CMB.TECH as the issuer of the merger consideration shares (the “Merger”).
ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory
prnewswire.com
2025-08-14 07:00:00ST. PAUL, Minn. , Aug. 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant to develop a modular G-Rex centric CAR T-cell manufacturing platform.
CMB.TECH Business update Q2 2025 results
globenewswire.com
2025-08-14 02:33:00Antwerp, Aug. 14, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its second quarter 2025 earnings prior to market opening on Thursday 28 August 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter. Due to the proximity of the expected closing date of the contemplated stock-for-stock merger between CMB.TECH and Golden Ocean Group Limited (“Golden Ocean”), CMB.TECH already provides preliminary figures related to the Q2 2025 results in this business update.
CMB.TECH's update on the Golden Ocean merger process
globenewswire.com
2025-08-11 03:26:00Antwerp, Aug. 11, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext Brussels: CMBT) (“CMB.TECH”) provides an additional market update on the progress of the contemplated stock-for-stock merger between CMB.TECH and Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) ("Golden Ocean").